Kevin Pantalone

Dr. Kevin Pantalone


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DBDavid T Broome
David T Broome
KPKevin Pantalone
Kevin Pantalone
SKSangeeta Rao R Kashyap
Sangeeta Rao R Kashyap
LPLouis H Philipson
Louis H Philipson
Maturity-onset diabetes of the young, or MODY-monogenic diabetes, is a not-so-rare collection of inherited disorders of non-autoimmune diabetes mellitus that remains insufficiently diagnosed despite increasing awareness. These cases are important to efficiently and accurately diagnose, given the clinical implications of syndromic features, cost-effective treatment regimen, and the potential impact on multiple family members. Proper recognition of the clinical manifestations, family history, and cost-effective lab and genetic testing provide the diagnosis. All patients must undergo a thorough history, physical examination, multigenerational family history, lab evaluation (glycated hemoglobin A1c [HbA1c], glutamic acid decarboxylase antibodies [GADA], islet antigen 2 antibodies [IA-2A], and zinc transporter 8 [ZnT8] antibodies). The presence of clinical features with 3 (or more) negative antibodies may be indicative of MODY-monogenic diabetes, and is followed by genetic testing. Molecular genetic testing should be performed before attempting specific treatments in most cases. Additional testing that is helpful in determining the risk of MODY-monogenic diabetes is the MODY clinical risk calculator (>25% post-test probability in patients not treated with insulin within 6 months of diagnosis should trigger genetic testing) and 2-hour postprandial (after largest meal of day) urinary C-peptide to creatinine ratio (with a ≥0.2 nmol/mmol to distinguish HNF1A- or 4A-MODY from type 1 diabetes). Treatment, as well as monitoring for microvascular and macrovascular complications, is determined by the specific variant that is identified. In addition to the diagnostic approach, this article will highlight recent therapeutic advancements when patients no longer respond to first-line therapy (historically sulfonylurea treatment in many variants).Learning Objectives: Upon completion of this educational activity, participants should be able to:Target Audience: This continuing medical education activity should be of substantial interest to endocrinologists and all health care professionals who care for people with diabetes mellitus.

22 July 2015 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
KPKevin Pantalone
Kevin Pantalone
THTodd M Hobbs
Todd M Hobbs
BWBrian J Wells
Brian J Wells
SKSheldon X Kong
Sheldon X Kong
MKMichael Kattan
Michael Kattan
RZRobert S Zimmerman
Robert S Zimmerman
Purpose To compare the prevalence of diabetes-related complications and comorbidities, clinical characteristics, glycemic control, and treatment patterns in patients with type 2 diabetes (T2D) within a large integrated healthcare system in 2008 vs 2013. Methods An electronic health record system was used to create a cross-sectional summary of all patients with T2D as on 1 July 2008 and 1 July 2013. Differences between the two data sets were assessed after adjusting for age, gender, race, and household income. Results In 2008 and 2013, 24 493 and 41 582 patients with T2D were identified, respectively, of which the majority were male (52.3% and 50.1%) and Caucasian (79% and 75.2%). The mean ages (years) were 64.8 and 64.3. The percentages of patients across the defined A1C categories were 64.3 and 66.7 for <7%, 21.1 and 18.8 for 7–7.9%, 7.8 and 7.5 for 8–8.9%, and 6.8 and 7.0 for ≥9% in 2008 and 2013, respectively. The most prevalent T2D-related comorbidities were hypertension (82.5% and 87.2%) and cardiovascular disease (26.9% and 22.3%) in 2008 and 2013, respectively. Thiazolidinedione and sulfonylurea use decreased, whereas metformin and dipeptidyl peptidase-4 inhibitor use increased in the 5-year period. Conclusions Patients with T2D are characterized by a high number of comorbidities. Over 85% of the patients had an A1C<8% within our integrated health delivery system in 2008 and 2013. In 2008 and 2013, metformin therapy was the most commonly utilized antidiabetic agent, and sulfonylureas were the most commonly utilized oral antidiabetic agent in combination with metformin. As integrated health systems assume greater shared financial risk in newer payment models, achieving glycemic targets (A1C) and the management of comorbidities will become ever-more important, for preventing diabetes-related complications, as well as to ensure reimbursement for the medical care that is rendered to patients with diabetes.

5 February 2009 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
KPKevin Pantalone
Kevin Pantalone
MKMichael Kattan
Michael Kattan
CYChanghong Yu
Changhong Yu
BWBrian J. Wells
Brian J. Wells
SASusana Arrigain
Susana Arrigain
RZRobert S. Zimmerman
Robert S. Zimmerman

1 June 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
AAAli Aminian
Ali Aminian
JBJames Bena
James Bena
KPKevin Pantalone
Kevin Pantalone
BBBartolome Burguera
Bartolome Burguera

27 June 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
RPRhea E. Powell
Rhea E. Powell
FZFrancesco Zaccardi
Francesco Zaccardi
CBChristine Beebe
Christine Beebe
XCXin Mei Chen
Xin Mei Chen
ACAlyssa Crawford
Alyssa Crawford
KKKamlesh Khunti
Kamlesh Khunti
Aims: To systematically investigate the effect of interventions to overcome therapeutic inertia on glycaemic control in individuals with type 2 diabetes. Materials and Methods: We electronically searched for randomized controlled trials or quasi‐experimental studies published between January 1, 2004 and December 31, 2019 evaluating the effect of interventions on glycated haemoglobin (HbA1c) control. Characteristics of included studies and HbA1c difference between intervention and control arms (main outcome) were extracted. Interventions were grouped as: care management and patient education; nurse or certified diabetes educator (CDE); pharmacist; or physician‐based. Results: Thirty‐six studies including 22 243 individuals were combined in nonlinear random‐effects meta‐regressions; the median (range) duration of intervention was 1 year (0.9 to 36 months). Compared to the control arm, HbA1c reduction ranged from: −17.7 mmol/mol (−1.62%) to −4.4 mmol/mol (−0.40%) for nurse‐ or CDE‐based interventions; −13.1 mmol/mol (−1.20%) to 3.3 mmol/mol (0.30%) for care management and patient education interventions; −9.8 mmol/mol (−0.90%) to −6.6 mmol/mol (−0.60%) for pharmacist‐based interventions; and −4.4 mmol/mol (−0.40%) to 2.8 mmol/mol (0.26%) for physician‐based interventions. Across the included studies, a reduction in HbA1c was observed only during the first year (6 months: −4.2 mmol/mol, 95% confidence interval [CI] −6.2, −2.2 [−0.38%, 95% CI −0.56, −0.20]; 1 year: −1.6 mmol/mol, 95% CI −3.3, 0.1 [−0.15%, 95% CI −0.30, 0.01]) and in individuals with preintervention HbA1c >75 mmol/mol (9%). Conclusions: The most effective approaches to mitigating therapeutic inertia and improving HbA1c were those that empower nonphysician providers such as pharmacists, nurses and diabetes educators to initiate and intensify treatment independently, supported by appropriate guidelines.

20 April 2018 in Diabetes Care
Verified
Journal Article
Open access
PDF file
KPKevin Pantalone
Kevin Pantalone
AMAnita D. Misra-Hebert
Anita D. Misra-Hebert
THTodd M. Hobbs
Todd M. Hobbs
XJXinge Ji
Xinge Ji
SKSheldon X. Kong
Sheldon X. Kong
RZRobert S. Zimmerman
Robert S. Zimmerman